Outsourcing-Pharma.com presents its weekly round-up of the latest appointments within the industry, including news from Quintiles, AMRI and PDI.
Christoph Schnorr has become head of the European research and development (R&D) consulting practice at Quintiles.
He joins the firm from Merck Serono where he was head of development operations.
In a news release, the firm said: “A physician by training, and with twenty years’ experience in the pharmaceutical industry, Schnorr brings extensive expertise across the whole drug development spectrum to Quintiles.”
AMRI has named Steven Hagen its new senior VP of pharmaceutical development and manufacturing.
He steps up to the role after serving as VP of the department since 2008. He first joined the firm as senior director of analytical quality services in 2005.
President and CEO Thomas D'Ambra said: “Under Dr. Hagen's leadership, AMRI has experienced growth within key sectors of AMRI's business.”
PDI has handed Gerald Melillo the role of president of sales services.
Previously the senior VP of business development, Melillo will take charge of all sales operations for the commercialisation services provider.
CEO Nancy Lurker said: "As a seasoned pharmaceutical executive, we are confident that his results-focused leadership style will continue to create strong shareholder value for our firm.”
Kline & Company has hired Richard Buoni and Jing Yuan onto its management team.
Formerly the senior director of North America supply chain for Checkpoint Systems, Buoni becomes VP for the firm.
Coming to the firm from her role as BD director at Johnson & Johnson, Yuan takes on the position of director of its management consulting business.
TGaS Advisors has appointed Tim Burke, Brian Voellmecke and Michele Wlodarczyk onto its board of directors and management advisors.
Burke joins the benchmarking firm from Pfizer, where he was director of business operations.
Both former IMS Helath employees, Voellmecke was global director of strategic alliance, and Wlodarczyk was senior offering manager for the longitudinal patient-level offerings.